Breaking News Instant updates and real-time market news.

EHTH

eHealth

$45.38

-0.85 (-1.84%)

, ARAY

Accuray

$3.97

0.09 (2.32%)

19:01
01/22/19
01/22
19:01
01/22/19
19:01

Fly Intel: After Hours Movers

UP AFTER EARNINGS: eHealth (EHTH) up 8.4% preliminary Q4 and FY19 guidance... after Accuray (ARAY) up 8.1%... Navient (NAVI) up 7.4%... IBM (IBM) up 6.1%... Conmed (CNMD) up 4.9%... ProPetro (PUMP) up 3.7%... TD Ameritrade (AMTD) up 1.7%... Territorial Bancorp (TBNK) up 1.1%. ALSO HIGHER: Aphria (APHA) up 4.4% after buyout offer from Green Growth. DOWN AFTER EARNINGS: Trinseo (TSE) down 10.7% after cutting Q4 guidance... Capital One (COF) down 4.1%... Quotient Technology (QUOT) down 2.6% after cutting Q4 guidance... Interactive Brokers (IBKR) down 1.3%. ALSO LOWER: PTC Therapeutics (PTCT) down 7.0% after equity offering. Movers as of 18:45ET.

EHTH

eHealth

$45.38

-0.85 (-1.84%)

ARAY

Accuray

$3.97

0.09 (2.32%)

NAVI

Navient

$10.87

-0.05 (-0.46%)

IBM

IBM

$122.34

-1.49 (-1.20%)

CNMD

Conmed

$66.62

-0.03 (-0.05%)

PUMP

ProPetro Holding

$14.96

-0.49 (-3.17%)

AMTD

TD Ameritrade

$54.96

-0.38 (-0.69%)

TBNK

Territorial Bancorp

$26.90

-0.26 (-0.96%)

APHA

Aphria

$7.07

0.41 (6.16%)

TSE

Trinseo

$48.54

-2.78 (-5.42%)

COF

Capital One

$83.38

-1.62 (-1.91%)

QUOT

Quotient Technology

$10.99

-0.55 (-4.77%)

IBKR

Interactive Brokers

$51.92

-2.82 (-5.15%)

PTCT

PTC Therapeutics

$33.08

-1.245 (-3.63%)

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 10

    Feb

  • 11

    Feb

  • 13

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 18

    May

  • 23

    Jan

  • 24

    Jan

EHTH eHealth
$45.38

-0.85 (-1.84%)

10/08/18
CANT
10/08/18
NO CHANGE
Target $39
CANT
Overweight
eHealth price target raised to $39 from $26 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for eHealth to $39 and reiterates an Overweight rating on the shares citing an improving growth outlook. After several years of investment, company is poised to drive stronger top line growth and expand margins, Halper tells investors in a research note. He believes eHealth's sales growth is likely to benefit from "strong" growth in Medicare, offset to some degree by declining Affordable Care Act individual and family plans. He views the stock's risk/reward trade-off as "compelling."
12/20/18
RHCO
12/20/18
NO CHANGE
Target $50
RHCO
Buy
eHealth price target raised to $50 from $30 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on eHealth to $50 and kept his Buy rating while also raising his FY19 EBITDA estimate to $36M from $26M and FY20 view to $56M from $39M. The analyst attributes the change to his "increased assumptions for Medicare member retention and cost-effective online enrollment of Medicare members." Sommer also cites his view that "Medicare annual enrollment period was robust and characterized by carriers competing aggressively to drive enrollment higher", which is a "favorable" backdrop for eHealth stock.
10/25/18
10/25/18
NO CHANGE

eHealth reports Q3 EPS (47c), consensus (36c)
Reports Q3 revenue $40.8M, consensus $35.52M.
12/20/18
RBCM
12/20/18
INITIATION
Target $57
RBCM
Outperform
eHealth initiated with an Outperform at RBC Capital
RBC Capital analyst George Hill initiated eHealth with an Outperform rating and a price target of $57, saying his thesis on the stock reflects a "unique way to invest in the convergent trends of the aging population, Medicare Advantage growth, healthcare's vertical integration trend, healthcare consumerism and technology." The analyst is positive on the company's position as an "online marketplace for the comparison and enrollment in health insurance plans, with a focus on the rapidly growing Medicare Advantage market" and expects it to generate 20% annual revenue growth with faster earnings for the next several years.
ARAY Accuray
$3.97

0.09 (2.32%)

04/10/18
RBCM
04/10/18
NO CHANGE
Target $6
RBCM
Sector Perform
Accuray can execute on replacement cycle, says RBC Capital
RBC Capital analyst Brandon Henry writes that the findings from his Radiation Oncologist survey suggest Accuray "can execute on its replacement cycle opportunity", but the company has to do more to convince the practitioners outside its installed base that its systems are sufficiently differentiated. Henry adds that the replacement cycle opportunity for Accuray's CyberKnife remains intact, with a more positive response rate by oncologists in Europe, though U.S. oncologists were less enthused in their response. The analyst keeps his Sector Perform rating and $6 price target on Accuray, forecasting the stock to perform in line with its peer group.
11/01/18
SBSH
11/01/18
UPGRADE
Target $3.9
SBSH
Neutral
Accuray upgraded to Neutral from Sell at Citi
Citi analyst Amit Hazan upgraded Accuray to Neutral and raised his price target for the shares to $3.90 from $3.50. The "long-anticipated" China quota announcement for the radiation therapy market came in well above expectations at 1,396 total systems, Hazan tells investors in a research note. He expects Accuray is now positioned to deliver above Street orders over the coming few years given its "prior success with Type A tenders in China last quota cycle." However, the analyst believes risks still remain in China around actual license award/allocation, new competition, and conversion of these orders into revenues.
NAVI Navient
$10.87

-0.05 (-0.46%)

01/16/19
JPMS
01/16/19
NO CHANGE
JPMS
JPMorgan resets ratings across Specialty Finance sector
The prospect of a prolonged government shutdown and global trade uncertainty threatens what has been "steady, reliable domestic growth," JPMorgan analyst Richard Shane tells investors in a research note on the Specialty Finance sector. Further, the analyst believes the outlook for Fed action has become more clouded. However, Shane thinks sentiment across his sector seems to reflect uncertainty, which gives him an "increasingly positive bias" to the group. He sees the most upside potential among consumer finance names, with late cycle uncertainty "potentially dampening" upside among commercial mortgage real estate investment trusts. Shane this morning upgraded a host of names: Navient (NAVI), OneMain Holdings (OMF) and KKR Real Estate Finance Trust (KREF) to Neutral from Underweight and TCG BDC (CGBD), Annaly Capital (NLY) and Apollo Commercial (ARI) to Overweight from Neutral. Today's downgrades are Santander Consumer (SC), BlackRock Capital Investment (BKCC), WhiteHorse Finance (WHF) to Underweight from Neutral along with PennantPark (PNNT) and Granite Point Mortgage (GPMT) to Neutral from Overweight.
01/16/19
JPMS
01/16/19
UPGRADE
Target $12
JPMS
Neutral
Navient upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Shane upgraded Navient to Neutral while lowering his price target for the shares to $12 from $13.
06/01/18
06/01/18
UPGRADE
Target $15.75

Outperform
Navient upgraded to Outperform with $15.75 price target at Wedbush
As previously reported, Wedbush analyst Henry Coffey upgraded Navient to Outperform from Neutral, stating that the company's new reporting structure helps him better appreciate the company's earnings outlook and suggests the company is likely to report modest growth in EPS and a total return of over 18% during the next 18 months. Coffey raised his estimates for Navient and increased his price target on the stock to $15.75 from $14.50.
06/01/18
WEDB
06/01/18
UPGRADE
WEDB
Outperform
Navient upgraded to Outperform from Neutral at Wedbush
IBM IBM
$122.34

-1.49 (-1.20%)

01/15/19
UBSW
01/15/19
NO CHANGE
Target $150
UBSW
Buy
IBM weakness a buying opportunity, says UBS
UBS analyst John Roy said the selloff in IBM appears to be overdone. The analyst believes the stock is reflecting some of the challenges the company is facing, but he expects the multiple to expand once its pending deals are closed. He believes 2019 could be a transitional year as its Red Hat deal closes, its software portfolio returns to organic growth, and its momentum in GBS remains strong. Roy reiterated his Buy rating and $150 price target on IBM shares.
12/20/18
SBSH
12/20/18
DOWNGRADE
Target $26
SBSH
Neutral
Citi downgrades Sanmina to Neutral, cuts IBM target to $125
Citi analyst Jim Suva downgraded Sanmina (SANM) to Neutral from Buy and lowered his price target for the shares to $26 from $35. The analyst also cut his price target for Neutral-rated IBM (IBM) to $125 from $165. The outlook for 2019 shows slowing growth across most end markets, Suva tells investors in a research note. As such, he expects tech companies to increase their M&A actions coupled with production or sourcing moves away from China.
01/15/19
STFL
01/15/19
NO CHANGE
Target $145
STFL
Buy
IBM price target lowered to $145 from $178 at Stifel
Stifel analyst David Grossman said he expects IBM's EPS and free cash flow to remain relatively flat in 2019 and 2020 on both a reported and pro forma basis before he sees growth resuming in 2021. He also noted that currency headwinds have increased significantly over the past three months, which is likely to impact reported revenue versus consensus. Grossman, who thinks the stock should set up favorably in a defensive market, keeps a Buy rating on IBM but lowered his price target for shares to $145 from $178.
01/15/19
NOMU
01/15/19
NO CHANGE
Target $160
NOMU
Buy
Nomura Instinet calls IBM 'preferred tech defensive play' for 2019
Nomura Instinet analyst Jeffrey Kvaal lowered his price target for IBM to $160 from $170 but keeps a Buy rating on the shares. The analyst reduced his estimates and price target to reflect unfavorable currency shifts. However, he expects IBM's Q4 to offer "stronger growth" in Strategic Imperatives, a Transaction Processing recovery, and a return to billings growth. IBM is Kvaal's preferred tech defensive play given its "high annuity revenue, a likely return to sales growth, and a low valuation."
CNMD Conmed
$66.62

-0.03 (-0.05%)

08/02/18
NEED
08/02/18
NO CHANGE
Target $83
NEED
Buy
CONMED price target raised to $83 from $73 at Needham
Needham analyst Mike Matson raised his price target on Conmed to $83 and kept his Buy rating after its Q2 revenue and earnings beat. The analyst notes the company's 7.4% increase in constant-currency revenue growth, 190bp gross margin expansion, and the resulting increases in SG&A and R&D spending. Matson expects Conmed to sustain its revenue growth of over 6% while exceeding consensus estimates.
10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
CONMED initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated CONMED with an Equal Weight rating and $78 price target.
12/14/18
PIPR
12/14/18
NO CHANGE
Target $74
PIPR
Neutral
Conmed acquisition of Buffalo Filter 'makes sense,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Conmed's acquisition of Buffalo Filter "makes sense" as it brings a faster growth asset with an above corporate average margin profile. Buffalo's product line is a nice strategic fit within Conmed's AirSeal and surgery franchise along with its expanding international footprint, O'Brien tells investors in a research note. That said, the analyst notes the deal lifts Conmed's leverage ratio to an "uncomfortable" five times. Leverage is a "negative to monitor going forward," says the analyst. Based on this factor and a lack of organic margin expansion in the core business, he keeps a Neutral rating on Conmed.
08/30/18
LEER
08/30/18
NO CHANGE
Target $81
LEER
Market Perform
CONMED price target raised to $81 from $76 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $81 from $76 to reflect recent multiple expansion for the group. The analyst reiterates a Market Perform rating on the shares.
PUMP ProPetro Holding
$14.96

-0.49 (-3.17%)

01/17/19
STFL
01/17/19
NO CHANGE
STFL
Stifel lowers Oilfield Services and Equipment estimates
Stifel analyst Stephen Gengaro said he expects overall E&P capital spending to be about flat in the U.S. market and he cut his forecast for U.S. drilling and completion activity based on the current WTI crude oil strip. He lowered his U.S rig count projections by 50 to 1,050 rigs in 2019 and by 100 to 1,150 rigs in 2020 and he cut his 2019 EBITDA forecast by roughly 10% on average. Based on the changes in estimates, Gengaro lowered his earnings expectations for the majority of the names he covers and cut his price targets on several. Among the largest target changes, he lowered his price target on Core Laboratories (CLB) to $86 from $110, cut his target on Emerge Energy (EMES) to $3 from $5, reduced his target on Halliburton (HAL) to $37 from $45 and trimmed his target on Superior Energy (SPN) to $5 from $9. Others in the space that Gengaro covers include Baker Hughes (BHGE), DMC Global (BOOM), Civeo (CVEO), Keane Group (FRAC), FTS International (FTSI), Liberty Oilfield Services (LBRT), National Oilwell (NOV), Oil States (OIS), Pioneer Energy (PES), ProPetro Holding (PUMP), RPC, Inc. (RES), Schlumberger (SLB), U.S. Silica (SLCA), Smart Sand (SND), Solaris Oilfield (SOI), Tenaris (TS), Tetra Technologies (TTI) and Weatherford (WFT).
01/17/19
COWN
01/17/19
UPGRADE
Target $24
COWN
Outperform
Cowen more positive on pressure pumping stocks, upgrades ProPetro
Cowen analyst Marc Bianchi upgraded ProPetro Holding (PUMP) to Outperform from Market Perform to reflect his more positive stance on pressure pumping stocks. With relatively more focus toward U.S onshore activity, and in light of "significantly" lower investors expectations and more attractive valuations, the analyst is more positive on pressure pumping. He sees completion activity growing in Q2 and beyond driving improved utilization and margins. Bianchi lowered his price target for ProPetro Holding shares to $24 from $25.
01/17/19
COWN
01/17/19
UPGRADE
COWN
Outperform
ProPetro Holding upgraded to Outperform from Market Perform at Cowen
01/15/19
LEHM
01/15/19
NO CHANGE
LEHM
Barclays upgrades ProPetro, downgrades FTS, RPC and U.S. Silica
Barclays analyst J. David Anderson upgraded ProPetro Holding (PUMP) to Overweight from Equal Weight while downgrading both FTS International (FTSI) and U.S. Silica (SLCA) to Equal Weight from Overweight and RPC, Inc. (RES) to Underweight from Equal Weight. The analyst recommends that investors take a "best of breed approach" in the first half of 2019 to the U.S. land service markets. He tells investors to opportunistically add to positions in the highest quality names in the North America-centric verticals: ProPetro, Cactus (WHD) and Apergy (APY). Anderson believes ProPetro deserves a premium multiple for its "differentiated model in an increasingly commoditized market." He downgraded FTS because of the company's "spot market vulnerability and higher balance sheet leverage." The analyst downgraded RPC to Underweight citing its pressure pumping business, a discount multiple for spot exposure, and its higher maintenance capex. And his downgrade of U.S. Silica reflects the proppant markets remaining "in disarray and under heavy pricing pressure as the industry struggles to acclimate to in-basin proliferation."
AMTD TD Ameritrade
$54.96

-0.38 (-0.69%)

11/30/18
GSCO
11/30/18
INITIATION
Target $60
GSCO
Neutral
TD Ameritrade initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Will Nance initiated coverage of the Online Brokers with an Attractive coverage view, stating that for the group on the whole he believes cyclical factors will drive fundamentals and valuation in the near term despite organic growth and pricing concerns. He started TD Ameritrade with a Neutral rating and $60 price target, stating that his estimates are roughly in-line with consensus. The bull thesis, that TD Ameritrade benefits the most in the group from more volatile markets and should see a multi-year increase in spread-based income, is largely reflected in consensus expectations, Nance believes.
01/22/19
MSCO
01/22/19
NO CHANGE
Target $57
MSCO
Overweight
Charles Schwab target raised to $57 ahead of winter update at Morgan Stanley
Morgan Stanley analyst Michael Cyprys said he has increased conviction in Charles Schwab (SCHW) shares after the company saw stronger organic deposit growth and broadly strong underlying growth metrics in Q4. He expects Charles Schwab to provide2019 guidance at the company's upcoming Winter Update on February 5 that should meet consensus expectations, but he also expects Schwab to beat those expectations over the course of 2019, as they havve done in prior years. He also expects Charles Schwab to give "more rational" pricing commentary this late in the cycle, which should support the stock and peers TD Ameritrade (AMTD) and E-Trade (ETFC), Cyprys tells investors. He raised his price target on Charles Schwab shares to $57 from $55 ahead of the update call and keeps an Overweight rating on the stock.
01/04/19
MSCO
01/04/19
NO CHANGE
MSCO
Morgan Stanley says buy TD Ameritrade ahead of earnings, negative on Virtu
Morgan Stanley analyst Michael Cyprys lowered his Q4 EPS estimates by 11% for the Asset Manager and Broker group given that the S&P 500 fell nearly 14% in the quarter, upending what had been a positive year for equity markets up until that point. For 2019, he favors the discount brokers - TD Ameritrade (AMTD), E-Trade (ETFC) and Charles Schwab (SCHW) - given their more defensive earnings profiles. Ahead of the Q4 earnings season he sees TD Ameritrade as "compelling" given its greater skew to trading revenues among the eBrokers, greater derivative mix and rising client cash levels, Cyprys tells investors. He also views concerns around commission price cuts as overdone as doe not expect Charles Schwab to cut, the analyst added. Ahead of Q4 reporting, Cyprys is negative on Virtu Financial (VIRT), as he thinks expectations are too high and notes the stock has recently outperformed.
11/19/18
11/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS with analyst Brennan Hawken saying he believes "misperceptions about late cycle risk" has created an attractive entry point for shares. 2. Helmerich & Payne (HP) upgraded two notches to Buy from Sell at SunTrust, to Buy from Neutral at Citi, and to Neutral from Underperform at Credit Suisse. 3. Viking Therapeutics (VKTX) upgraded to Strong Buy from Outperform at Raymond James with analyst Steven Seedhouse saying he thinks TR-B remains one of the most promising mechanisms with proof-of-concept in NASH based on VK2809 and MGL-3196 data presented and conversations with physicians. 4. Big Lots (BIG) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he expects a "strong" tax refund season in early 2019 for lower/moderate-income families. 5. Booking Holdings (BKNG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Robert Coolbrith saying he believes current valuation offers a favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TBNK Territorial Bancorp
$26.90

-0.26 (-0.96%)

APHA Aphria
$7.07

0.41 (6.16%)

01/18/19
CIBC
01/18/19
INITIATION
CIBC
Neutral
Aphria initiated with a Neutral at CIBC
CIBC analyst John Zamparo initiated Aphria (APHA) with a Neutral rating and C$10 price target. He expects cannabis to follow the course of other newborn industries, where investors rush to pour capital into the sector and then very few companies live up to their lofty expectations while the industries develop. The debate over the value of Aphria's international assets and corporate governance concerns have obscured the value of the company's quality domestic assets, but concerns about corporate governance and capital allocation are not without some validity, Zamparo tells investors. He also initiated coverage on two other cannabis stocks, Canopy Growth (CGC) and Cronos Group (CRON), both with Outperformer ratings this morning, citing his favorable view of their management teams.
TSE Trinseo
$48.54

-2.78 (-5.42%)

11/15/18
SBSH
11/15/18
UPGRADE
Target $58
SBSH
Buy
Citi upgrades Trinseo to Buy on favorable risk/reward post selloff
Citi analyst Eric Petrie upgraded Trinseo to Buy from Neutral with an unchanged price target of $58. The analyst sees a favorable risk/reward following the recent pullback in the shares. The "knee-jerk" reaction to an initial investigation for potential violation of antitrust rules into styrene purchasing activity by the European Commission that could result in assessed fines is likely overdone, Petrie tells investors in a research note. The analyst says his basic fine estimate range of $135M-$180M is below investors' worst-case scenario at 10% of overall sales and that his assumptions could prove to be aggressive.
12/07/18
JEFF
12/07/18
DOWNGRADE
Target $55
JEFF
Hold
Trinseo downgraded to Hold from Buy at Jefferies
Jefferies analyst Laurence Alexander downgraded Trinseo to Hold and lowered his price target for the shares to $55 from $80. The analyst is now more cautious on the Chemicals space, saying he expects recession risk signals to continue emerging over the next few quarters. He believes the restock cycle after the Chinese New Year could be balanced by deceleration in U.S. end-markets in the second half of 2019 and 2020.
11/15/18
SBSH
11/15/18
UPGRADE
Target $58
SBSH
Buy
Trinseo upgraded to Buy from Neutral at Citi
Citi upgraded Trinseo to Buy with a $58 price target.
11/13/18
TUDR
11/13/18
DOWNGRADE
TUDR
Hold
Trinseo downgraded to Hold from Buy at Tudor Pickering
COF Capital One
$83.38

-1.62 (-1.91%)

11/16/18
OPCO
11/16/18
NO CHANGE
Target $114
OPCO
Outperform
American Express new top credit card pick, says Oppenheimer
Oppenheimer analyst Dominick Gabriele said his new top pick in the credit card space is American Express (AXP) vs. Capital One (COF), as he sees more levers to drive EPS growth upside. In a research note to investors, Gabriele says TTM delinquency formation trends among his credit card coverage reflect a benign credit environment while net charge offs are likely to remain subdued.
12/10/18
BARD
12/10/18
UPGRADE
BARD
Outperform
Capital One upgraded to Outperform from Neutral at Baird
12/10/18
BARD
12/10/18
UPGRADE
Target $101
BARD
Outperform
Capital One valuation 'too compelling to ignore,' says Baird
Baird analyst David George upgraded Capital One (COF) to Outperform from Neutral with a $101 price target, telling investors in a research note that the valuation is "too compelling to ignore" for this "quality" franchise. George acknowledges the high leverage to consumer lending and more limited credit visibility, but thinks bear-case earnings power in a recession is $9-$10/sh, and valuation still looks reasonable in this stressed scenario. George says Wells Fargo (WFC), Citizens Financial (CFG) and PNC (PNC) remain his other top Outperform-rated ideas.
12/10/18
12/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kratos Defense (KTOS) upgraded to Buy from Neutral at Goldman Sachs with analyst Noah Poponak citing the company's "long list of new growth programs," many of which are yet to fully develop, and expects organic revenue to grow nearly 20% in 2019 and 2020 before stabilizing at a sustained double digit rate "through the middle of the next decade." 2. SL Green Realty (SLG) upgraded to Buy from Hold at Deutsche Bank with analyst Derek Johnston sayinh he is increasingly bullish on the New York City leasing environment. 3. Five Below (FIVE) upgraded to Buy from Hold at Loop Capital Loop Capital with analyst Anthony Chukumba saying Five Below is more "economic downturn resistant" than most retailers and has a long square footage growth runway ahead of it. 4. U.S. Steel (X) upgraded to Neutral from Sell at UBS with analyst Andreas Bokkenheuser saying he remains cautious on the sector, as he expect steel prices to trade down to $660/st from $760/st spot. 5. Capital One (COF) upgraded to Outperform from Neutral at Baird with analyst David George saying the valuation is "too compelling to ignore" for this "quality" franchise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
QUOT Quotient Technology
$10.99

-0.55 (-4.77%)

03/13/18
FANA
03/13/18
NO CHANGE
Target $18
FANA
Overweight
Quotient Technology price target raised to $18 from $16 at First Analysis
First Analysis analyst Lawrence Berlin raised his price target for Quotient Technology to $18 and keeps an Overweight rating on the name. Meetings with CFO Ron Fior reinforced the analyst's confidence in the company's prospects for revenue growth rates above 20% fueled by growing use of digital coupons by consumer packaged goods.
08/01/18
RBCM
08/01/18
DOWNGRADE
RBCM
Sector Perform
Quotient Technology downgraded to Sector Perform from Outperform at RBC Capital
08/01/18
RBCM
08/01/18
DOWNGRADE
Target $17
RBCM
Sector Perform
Quotient Technology downgraded to Sector Perform at RBC Capital on mixed quarter
As reported earlier, RBC Capital analyst Mark Mahaney downgraded Quotient Technology to Sector Perform from Outperform and kept his $17 price target. The analyst cites a split quarter of better than expected revenues with upgrade in guidance and a miss in EBITDA with downside revision in guidance, along with a lower than expected gross margin driven by the shift away from Promotions and toward Media Revenue. Mahaney states that while his long-term view of Quotient Technology remains positive, he prefers a "more compelling" stock entry point with a better gross margin story.
02/21/18
OPCO
02/21/18
INITIATION
Target $16
OPCO
Outperform
Quotient Technology initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jason Helfstein started Quotient Technology with an Outperform rating and $16 price target as he believes digital paperless growth is an underappreciated secular tailwind.
IBKR Interactive Brokers
$51.92

-2.82 (-5.15%)

12/10/18
WELS
12/10/18
NO CHANGE
Target $46
WELS
Underperform
Interactive Brokers price target lowered to $46 from $52 at Wells Fargo
Wells Fargo analyst Christopher Harris lowered his price target for Interactive Brokers to $46 from $52 saying growth is slowing. The analyst remains cautious on the stock given the weakening trends in its core business, its exposure to Asia and its high relative valuation. He reiterates an Underperform rating on the shares.
11/30/18
GSCO
11/30/18
INITIATION
Target $58
GSCO
Neutral
Interactive Brokers initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Will Nance initiated coverage of the Online Brokers with an Attractive coverage view, stating that for the group on the whole he believes cyclical factors will drive fundamentals and valuation in the near term despite organic growth and pricing concerns. He started Interactive Brokers with a Neutral rating and $58 price target, stating that he views it as the most cyclically exposed among the group. Over time, he expects the growth in its white label introducing brokers channel will continue to drive a mix shift towards NII and away from commissions, Nance added.
04/18/18
WELS
04/18/18
NO CHANGE
Target $60
WELS
Underperform
Interactive Brokers price target raised to $60 from $52 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for Interactive Brokers to $60 from $52 following quarterly results. The analyst reiterates an Underperform rating on the shares.
07/18/18
RHCO
07/18/18
NO CHANGE
Target $71
RHCO
Hold
Interactive Brokers price target lowered to $71 from $75 at SunTrust
SunTrust analyst Douglas Mewhirter lowered his price target on Interactive Brokers to $71 and kept his Hold rating after its mixed Q2 results. The analyst notes the company posted slower account growth and Daily Average Revenue Trades metrics, even as its net interest income improved and its profits benefited from the lower tax rate. As a result of the lower forecasted commissions revenues, Mewhirter also lowers his Interactive Brokers' FY18 EPS estimate to $2.16 from $2.23.
PTCT PTC Therapeutics
$33.08

-1.245 (-3.63%)

10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
11/12/18
CANT
11/12/18
NO CHANGE
Target $61
CANT
Overweight
PTC Therapeutics price target lowered to $61 from $66 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young lowered her price target for PTC Therapeutics to $61 on expectations the company's expense run-rate will be higher from here as it invests in new programs like gene therapy. The analyst, however, still sees upside in the shares driven by her confidence in the risdiplam. She reiterates an Overweight rating on the shares.
10/03/18
BOFA
10/03/18
UPGRADE
BOFA
Neutral
PTC Therapeutics upgraded to Neutral from Underperform at BofA/Merrill

TODAY'S FREE FLY STORIES

YEXT

Yext

$23.00

0.33 (1.46%)

22:43
03/18/19
03/18
22:43
03/18/19
22:43
Syndicate
Yext 6.1M share Spot Secondary priced at $21.50 »

Goldman Sachs is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

WU

Western Union

$18.17

-0.2 (-1.09%)

22:42
03/18/19
03/18
22:42
03/18/19
22:42
Hot Stocks
Western Union to partner with emerging-market moble network Thunes »

Western Union has teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$28.17

0.09 (0.32%)

22:40
03/18/19
03/18
22:40
03/18/19
22:40
Hot Stocks
Mylan conducts voluntary recall of Levoleucovorin Injection »

Mylan Institutional LLC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYHT

Shineco

$0.67

0.0003 (0.04%)

20:43
03/18/19
03/18
20:43
03/18/19
20:43
Recommendations
Shineco analyst commentary  »

Shineco establishing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$44.97

0.33 (0.74%)

20:31
03/18/19
03/18
20:31
03/18/19
20:31
Hot Stocks
Activision Blizzard unveils Call of Duty: Mobile edition »

Activision, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$372.10

-6.795 (-1.79%)

20:28
03/18/19
03/18
20:28
03/18/19
20:28
Hot Stocks
Boeing CEO says 'work progressing thoroughly' to understand cause for 737 crash »

In a letter, Boeing CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    May

GPX

GP Strategies

$12.57

-1.745 (-12.19%)

20:25
03/18/19
03/18
20:25
03/18/19
20:25
Recommendations
GP Strategies analyst commentary at Barrington »

GP Strategies organic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

MIK

Michaels

$11.79

0.11 (0.94%)

, DSW

DSW

$25.30

-0.09 (-0.35%)

20:25
03/18/19
03/18
20:25
03/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.79

0.11 (0.94%)

DSW

DSW

$25.30

-0.09 (-0.35%)

HDS

HD Supply

$43.09

0.09 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

, AMZN

Amazon.com

$1,742.00

29.29 (1.71%)

20:19
03/18/19
03/18
20:19
03/18/19
20:19
Hot Stocks
Nvidia to partner with Amazon on bringing AI to connected devices »

NVIDIA (NVDA) announced a…

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

AMZN

Amazon.com

$1,742.00

29.29 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

MEOH

Methanex

$57.22

1.68 (3.02%)

19:57
03/18/19
03/18
19:57
03/18/19
19:57
Hot Stocks
Methanex confirms M&G Investment letter, urges shareholders take no action »

Methanex confirms that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDS

HD Supply

$43.09

0.09 (0.21%)

19:55
03/18/19
03/18
19:55
03/18/19
19:55
Earnings
HD Supply sees FY19 EPS $3.52-$3.81, consensus $3.64 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

HDS

HD Supply

$43.09

0.09 (0.21%)

19:53
03/18/19
03/18
19:53
03/18/19
19:53
Earnings
HD Supply sees Q1 EPS 75c-84c, consensus 85c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

HDS

HD Supply

$43.09

0.09 (0.21%)

19:52
03/18/19
03/18
19:52
03/18/19
19:52
Earnings
HD Supply reports Q4 adjusted EPS 70c, consensus 67c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Mar

CASA

Casa Systems

$8.89

-0.06 (-0.67%)

19:47
03/18/19
03/18
19:47
03/18/19
19:47
Initiation
Casa Systems initiated at DA Davidson »

Casa Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCI

Crown Castle

$124.67

-0.41 (-0.33%)

19:46
03/18/19
03/18
19:46
03/18/19
19:46
Downgrade
Crown Castle rating change at Deutsche Bank »

Crown Castle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARPO

Aerpio Pharmaceuticals

$1.22

-2.915 (-70.58%)

19:39
03/18/19
03/18
19:39
03/18/19
19:39
Downgrade
Aerpio Pharmaceuticals rating change at Guggenheim »

Aerpio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

LIVX

LiveXLive Media

$6.30

0.19 (3.11%)

19:37
03/18/19
03/18
19:37
03/18/19
19:37
Initiation
LiveXLive Media initiated at Maxim »

LiveXLive Media initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 30

    Apr

  • 01

    May

AKBA

Akebia

$8.19

0.01 (0.12%)

19:31
03/18/19
03/18
19:31
03/18/19
19:31
Recommendations
Akebia analyst commentary at Piper Jaffray »

Akebia investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

VALE

Vale

$13.28

0.11 (0.84%)

19:18
03/18/19
03/18
19:18
03/18/19
19:18
Periodicals
Vale to resume activities at port after court injunction, Reuters reports »

Vale said Friday that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

TROX

Tronox

$12.09

0.2 (1.68%)

19:00
03/18/19
03/18
19:00
03/18/19
19:00
Hot Stocks
Tronox to present National Titanium Dioxide deal to FTC »

Tronox confirmed that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYMTF

Hyundai Motor

$0.00

(0.00%)

, HYMLF

Hyundai Motor Co

$0.00

(0.00%)

18:58
03/18/19
03/18
18:58
03/18/19
18:58
Hot Stocks
Connecticut AG announces probe into Hyundai, Kia fires »

Connecticut Attorney…

HYMTF

Hyundai Motor

$0.00

(0.00%)

HYMLF

Hyundai Motor Co

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNH

Syneos Health

$47.42

0.49 (1.04%)

, TLRY

Tilray

$72.15

-0.38 (-0.52%)

18:54
03/18/19
03/18
18:54
03/18/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SYNH

Syneos Health

$47.42

0.49 (1.04%)

TLRY

Tilray

$72.15

-0.38 (-0.52%)

EOLS

Evolus

$23.80

-1.02 (-4.11%)

AMRS

Amyris

$3.83

-0.1 (-2.54%)

FOE

Ferro

$18.88

0.125 (0.67%)

REV

Revlon

$19.39

0.42 (2.21%)

AKBA

Akebia

$8.19

0.01 (0.12%)

TORC

ResTORbio

$8.97

0.27 (3.10%)

TACO

Del Taco

$10.60

0.47 (4.64%)

HQY

HealthEquity

$82.86

0.76 (0.93%)

CVTI

Covenant Transportation

$21.43

-0.4 (-1.83%)

YEXT

Yext

$23.00

0.33 (1.46%)

WAGE

WageWorks

$39.59

1.875 (4.97%)

TWO

Two Harbors

$14.26

0.07 (0.49%)

AGS

PlayAGS

$25.65

-0.89 (-3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 19

    Mar

  • 21

    Mar

  • 17

    Apr

  • 16

    May

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

AAPL

Apple

$188.03

1.83 (0.98%)

18:52
03/18/19
03/18
18:52
03/18/19
18:52
Periodicals
Apple stops iOS 12.1.3 code signing after iOS 12.1.4 launch, AppleInsider says »

Apple has stopped signing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$108.52

9.8 (9.93%)

, FIS

FIS

$108.14

-0.73 (-0.67%)

18:41
03/18/19
03/18
18:41
03/18/19
18:41
Downgrade
Worldpay, FIS rating change at BMO Capital »

Worldpay downgraded to…

WP

Worldpay

$108.52

9.8 (9.93%)

FIS

FIS

$108.14

-0.73 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 04

    Apr

ERIC

Ericsson

$9.56

-0.075 (-0.78%)

18:32
03/18/19
03/18
18:32
03/18/19
18:32
Hot Stocks
Ericsson selected by TDC to roll out commercial 5G in Denmark »

Ericsson has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.